Genzyme, Isis deal
Isis and partner Genzyme revised a January deal that granted Genzyme exclusive rights to develop and commercialize Isis’ mipomersen for hypercholesterolemia and follow-on compounds. The updated terms follow delayed regulatory timelines for the compound’s beachhead indication - homozygous familial hypercholesterolemia (HoFH) - and the much larger indications of patients with heterozygous familial hypercholesterolemia (HeFH) and routine high cholesterol who are at high cardiovascular risk (see BioCentury, May 19).
Under the revision, Isis will now fund up to the first $125 million in development funding; previously, it had been up to $75 million. Isis also is eligible to receive $75 million in accelerated milestones related to sales in the HeFH indication. All other terms of the deal remain unchanged (see BioCentury, Jan. 14). ...